Resources

Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C

Showing 51 to 60 of 371 resources

  • Drug-related infectious diseases in Europe
    This report from the European Monitoring Centre for Drugs and Drug Addiction provides an overview of infectious disease surveillance data, outbreak investigations, and prevention and control measures among people who inject drugs in Europe up to February 2019, including viral hepatitis.
    UK, Rest of World 16 Jul 2019 Reports & Research PDF
  • Drug-related infectious diseases in Europe
    This report provides an update on infectious diseases related to drug use in Europe for the period up to June 2016. It covers the most recent data both on infectious diseases among people who inject drugs in Europe, collected with the European Monitoring Centre for Drugs and Drug Addiction Drug-related infectious diseases (DRID) indicator, and on the responses in the area. It includes highlights and new findings discussed during the DRID indicator’s annual expert meeting, held in Lisbon on 6–8 June 2016.
    Rest of World Reports & Research PDF
  • Drug-related infectious diseases in Europe: Update from the EMCDDA expert network, 2020
    This 2020 update on drug-related infectious diseases from the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020. It highlights some recent innovative responses to the problem and argues that early diagnosis through testing as well as improving links to treatment and care are crucial steps towards reaching global health goals.
    UK, Rest of World Reports & Research, Strategy & Planning PDF
  • EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
    These EASL Clinical Practice Guidelines (CPGs) are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with acute and chronic HCV infections. These guidelines apply to therapies that are approved at the time of their publication.
    UK, Rest of World 2014 Training, Reports & Research, Tools & Templates PDF
  • EASL Recommendations on Treatment of Hepatitis C 2016
    These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the current optimal management of patients with acute and chronic HCV infections. These recommendations apply to therapies that have been approved by the European Medicines Agency and other national European agencies at the time of their publication.
    Rest of World Sep 2016 Other, Reports & Research PDF
  • EASL Recommendations on Treatment of Hepatitis C: 2014
    These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decisionmaking process by describing the optimal management of patients with acute and chronic HCV infections. These guidelines apply to therapies that will be approved within less than 6 months at the time of their publication.
    UK Apr 2014 Reports & Research, Tools & Templates, Strategy & Planning PDF
  • East Midlands Specialised Commissioning Group Commissioning Policy for Hepatitis C Treatments
    This commissioning policy paper was produced for the treatment of patients with Hepatitis C in the East Midlands, with the aim of providing and ensuring equity, consistency and clarity in approach to treatment across the region. The document sets out the position of East Midlands Specialised Commissioning Group PCTs in respect of treatment for Hepatitis C for its current and future patients, outlining the treatment regimens for the various different genotypes of Hepatitis C using combination therapy (pegylated interferon alpha and weight-based ribavirin).
    East Midlands Jun 2009 Case study, Tools & Templates, Strategy & Planning PDF
  • Eliminating Hepatitis C in England
    In September 2017, the All-Party Parliamentary Group (APPG) on Liver Health launched an inquiry into achieving the elimination of hepatitis C in England. Three oral evidence sessions were held in October, featuring a range of expert stakeholders answering questions from APPG members. The APPG also received written submissions of evidence from individuals and organisations. Following the inquiry this report, 'Eliminating Hepatitis C in England', was produced, gathering the evidence received and setting out recommendations for action to ensure a hepatitis C-free England.
    England Reports & Research, Strategy & Planning PDF
  • Eliminating Hepatitis C in Scotland: A Call to Action
    The Hepatitis C Trust, following an inquiry held with the cross-party Scottish Hepatitis C Parliamentary Champions group, published a report, 'Eliminating Hepatitis C in Scotland: A Call to Action'. The report looks in detail at Scotland's approach to hepatitis C, focusing on the need for an elimination strategy, awareness, prevention, testing & diagnosis, linkage to care, access to treatment and funding. The report also features a series of recommendations for action to boost Scotland's progress towards achieving elimination.
    UK, Scotland Reports & Research, Strategy & Planning PDF
  • EMCDDA on models of care for hepatitis C in drugs services
    The European Monitoring Centre for Drugs and Drug Addiction published 'Hepatitis C: new models of care for drugs services' in July 2019. This aims to highlight the importance of targeting people who inject drugs as a key population for the elimination of hepatitis C in Europe and to show innovative practice in the form of 11 case studies (three of which are from England). The report provides key insights into the results, impact, sustainability and transferability of each practice to guide the implementation of these new models of care in other countries and settings.
    UK, Rest of World, England, Greater London 29 Jul 2019 Reports & Research, Strategy & Planning PDF

Pages